With BET inhibitors being able to sturdily repress both RAS and RhoA activities and with the fact that amoeboid movement facilitates the dissemination of DLBCL [16], it is plausible that combinative strategies tackling the mechanism adopted by lymphoma cells for their propagation may further improve the treatment outcome in these patients. The gene discussed is RHOA; the disease is lymphoma.